Canada · Delayed Price · Currency is CAD Entheon Biomedical Statistics
Total Valuation
CSE:ENBI has a market cap or net worth of CAD 1.66 million. The enterprise value is 1.25 million.
| Market Cap | 1.66M |
| Enterprise Value | 1.25M |
Important Dates
The last earnings date was Monday, June 30, 2025.
| Earnings Date | Jun 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:ENBI has 13.86 million shares outstanding. The number of shares has increased by 56.84% in one year.
| Current Share Class | 13.86M |
| Shares Outstanding | 13.86M |
| Shares Change (YoY) | +56.84% |
| Shares Change (QoQ) | +35.87% |
| Owned by Insiders (%) | 2.02% |
| Owned by Institutions (%) | n/a |
| Float | 13.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.81 |
| P/TBV Ratio | 3.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.48 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.75
| Current Ratio | 27.75 |
| Quick Ratio | 26.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.74% and return on invested capital (ROIC) is -63.44%.
| Return on Equity (ROE) | -98.74% |
| Return on Assets (ROA) | -58.79% |
| Return on Invested Capital (ROIC) | -63.44% |
| Return on Capital Employed (ROCE) | -84.94% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -360,401 |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.00% in the last 52 weeks. The beta is 1.56, so CSE:ENBI's price volatility has been higher than the market average.
| Beta (5Y) | 1.56 |
| 52-Week Price Change | +60.00% |
| 50-Day Moving Average | 0.10 |
| 200-Day Moving Average | 0.16 |
| Relative Strength Index (RSI) | 71.98 |
| Average Volume (20 Days) | 12,624 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -370,463 |
| Pretax Income | -360,401 |
| Net Income | -360,401 |
| EBITDA | n/a |
| EBIT | -370,463 |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 409,384 in cash and n/a in debt, giving a net cash position of 409,384 or 0.03 per share.
| Cash & Cash Equivalents | 409,384 |
| Total Debt | n/a |
| Net Cash | 409,384 |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 436,145 |
| Book Value Per Share | 0.03 |
| Working Capital | 431,145 |
Cash Flow
| Operating Cash Flow | -389,753 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:ENBI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -56.84% |
| Shareholder Yield | n/a |
| Earnings Yield | -21.67% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 1, 2024. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |